Poor performance status and brain metastases treatment: who may benefit from the stereotactic radiotherapy?
- 15 February 2021
- journal article
- research article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 152 (2) , 383-393
Abstract
Background Poor Performance Status (PS) of cancer patients, defined as PS score 2–3, is an impediment for many drug- and irradiation-based treatments, supported by the trials that exclude subjects with PS < 1. Reports on the benefits of stereotactic radiotherapy (SRT) for brain metastases (BMs) in poor PS patients are scarce. We sought to review the characteristics and survival outcomes of this cohort, to assess who may benefit most from SRT. Methods We retrospectively evaluated 73 patients with PS 2 or 3 (63 and 10 cases) treated with SRT for 150 BMs from 2012 to 2018. Patients’ characteristics and post-SRT survival, stratified by concomitant systemic treatment (CST) were assessed using the Kaplan–Meier method (p-value < 0.05). Results Non-small cell lung cancer was the most frequent primary tumor. Extracranial metastases were present in 86.3% of patients. The median overall survival (mOS) after SRT was estimated as 6.0 months (range 0.2–37.7), with 6- and 12-month survival rates of 51.0% and 21.0%, respectively. CST was administrated to 59.7% of patients (immunotherapy, target therapy or chemotherapy). Patients treated with CST presented larger mOS (6.7 vs. 4.4 months for patients treated with SRT alone, p = 0.3), and better 6- and 12-month survival rates (59% and 24% vs. 37% and 18% in patients not treated with CST). Conclusions Survival rate after SRT for BMs in poor performance patients, especially with PS 2, can justify SRT, in particular if an effective systemic treatment is available. Both SRT and CST should be more accessible for these patients in clinical practice.Keywords
Funding Information
- SEOR-CRIS Foundation
This publication has 38 references indexed in Scilit:
- Multimodality treatment of brain metastases: an institutional survival analysis of 275 patientsWorld Journal of Surgical Oncology, 2011
- Diagnosis-Specific Prognostic Factors, Indexes, and Treatment Outcomes for Patients With Newly Diagnosed Brain Metastases: A Multi-Institutional Analysis of 4,259 PatientsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guidelineJournal of Neuro-Oncology, 2009
- Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trialThe Lancet Oncology, 2009
- Patient‐physician disagreement regarding performance status is associated with worse survivorship in patients with advanced cancerCancer, 2008
- Predicting survival in patients with advanced diseaseEuropean Journal of Cancer, 2008
- Prevalence of Poor Performance Status in Lung Cancer Patients: Implications for ResearchJournal of Thoracic Oncology, 2008
- Microsurgery plus whole brain irradiation versus Gamma Knife surgery alone for treatment of single metastases to the brain: a randomized controlled multicentre phase III trialJournal of Neuro-Oncology, 2007
- Prognostic factors in brain metastases: should patients be selected for aggressive treatment according to recursive partitioning analysis (RPA) classes?International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2000
- Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trialsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1997